Market Report by Application, Distribution Channel, Route of Administration and Company Analysis, 2025-2033" has been added ...

Ngenla, a hormone drug from partners Pfizer and Opko Health, is now FDA approved for treating children with growth hormone deficiency. The once-weekly injectable biologic will compete against an ...

Five-year follow-up data from the Phase 3 ARCHES trial shows XTANDI (enzalutamide) plus androgen deprivation therapy (ADT) reduces risk of death by 30% After a median follow-up of 61.4 months, ...

Human growth hormone (HGH) is a hormone that’s essential to our development. Most people produce enough HGH throughout their lifetime. But for those with a deficiency in growth hormone (or a few other ...